Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer

A. O. Romero, J. E. Perez, M. A. Cuevas, J. A. Lacava, C. L. Sabatini, M. E. Dominguez, R. Rodriguez, M. R. Barbieri, E. H. Ortiz, M. A. Salvadori, L. A. Romero Acuña, J. M. Romero Acuña, M. J. Langhi, S. Amato, M. R. Machiavelli, B. A. Leone, C. T. Vallejo, V. Lorusso, M. DeLena

Research output: Contribution to journalArticlepeer-review

Abstract

A phase II trial was performed to evaluate the efficacy and toxicity of a double modulation of 5-fluorouracil (5-FU) by methotrexate (MTX) and L- leucovorin (L-LV) in patients with advanced recurrent (inoperable) or metastatic colorectal carcinoma (ACC). Between July 1993 and October 1995, 41 patients with ACC received a regimen that consisted of MTX 150 mg/m2 i.v., infused over a 20-minute period at hour 0, followed 19 hours later by L-LV 250 mg/m2 in a 2-hour i.v. infusion. 5-FU, 900 mg/m2, was administered by i.v. push injection at hour 20. Beginning 24 hours after MTX administration, all patients received four doses of L-LV, 15 mg/m2 i.m., every 6 hours. Cycles were repeated every 15 days. Two patients were not assessable for response. Objective regression was observed in 11 of 39 (28%) patients, [95% confidence interval (CI), 14-42%]. One (2%) patient achieved complete response (CR) and 10 (26%) partial response (PR). No change was recorded in 15 (39%) patients and progressive disease was noted in 13 (33%) patients. The median time to treatment failure was 6 months and the median survival time was 10 months. Toxicity was within acceptable limits, but one therapy- related death due to severe leukopenia was observed. The dose-limiting toxicity was mucositis. Eight episodes of grade 3 or 4 stomatitis were observed, and were responsible for dosage modifications of MTX and 5-FU. In conclusion, further in experimental and clinical studies are clearly necessary in order to design the best modulatory strategy of 5-FU.

Original languageEnglish
Pages (from-to)94-98
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume21
Issue number1
DOIs
Publication statusPublished - Feb 1998

Keywords

  • 5-FU
  • Biomodulation
  • Colorectal cancer
  • L-leucovorin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Double modulation of 5-fluorouracil by methotrexate and high-dose K- leucovorin in advanced colorectal cancer'. Together they form a unique fingerprint.

Cite this